disease - International Pharmaceutical Industry

Volume 16 Issue 1

Why is Real World Data the Key to Rare Disease Success?

The quest to understand and treat rare diseases is among the most challenging and vital missions in healthcare today. As the industry seeks innovative solutions, Rea...

15 April 2024 Volume 16 Issue 1 | Editorial Archive Challenging | data

Continue Reading →

Volume 15 Issue 4

IMI Mobilise-D: The Next Generation of Mobility Research

Mobility represents an important marker of health, and a slow walking speed is associated with a greater risk of disease, cognitive decline, risk of falls and even e...

19 December 2023 Volume 15 Issue 4 chronic | cognitive decline

Continue Reading →

Volume 15 Issue 3

A New Age of Pharmaceutical Innovation

IPI Speaks with Dr Patrick Larcier, Senior Director, Strategy Product Development Solutions, EU & US, of PharmaLex, on Next-generation Small Molecules Q: Can ...

29 September 2023 Volume 15 Issue 3 Age | biotechnology

Continue Reading →

Volume 15 Issue 3

Promising Advances in Plasma Proteomics for Early Disease Detection and Personalised Treatments

The early detection of disease poses a substantial challenge in the field of human health, necessitating the development of more accurate biomarkers, enhanced patien...

29 September 2023 Volume 15 Issue 3 advances | biomarkers

Continue Reading →

News

Leading Alzheimer's Disease scientist joins NeuroCog Trials

Dr. Kathleen Anne Welsh-Bohmer, a specialist in Alzheimer’s Disease (AD) research, has joined the scientific leadership team at NeuroCog Trials (NCT) as the Vice...

17 July 2018 News alzheimer | disease

Continue Reading →

News

Igniting hope for people living with chronic kidney disease

"Back to the Wall -- Ignite Hope of Life" was officially launched at the 16th Asian Pacific Congress of Nephrology (APCN) in Beijing. David Grier, Ha...

3 April 2018 News ACPN | Beijing

Continue Reading →

News

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-...

20 November 2017 News allogeneic | anti-inflammatory

Continue Reading →

News

Locus Biosciences raises $19 million series A for CRISPR-Cas3 Antimicrobials

Locus Biosciences has closed $19 million in Series A funding led by venture capital firm ARTIS Ventures with additional financing from notable institutional investor...

17 November 2017 News antibiotic | antimicrobial

Continue Reading →